Gilead Sciences, Inc. $GILD Holdings Decreased by Foundation Resource Management Inc.

Foundation Resource Management Inc. reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 98,374 shares of the biopharmaceutical company’s stock after selling 3,773 shares during the period. Gilead Sciences accounts for approximately 1.2% of Foundation Resource Management Inc.’s holdings, making the stock its 26th biggest position. Foundation Resource Management Inc.’s holdings in Gilead Sciences were worth $14,663,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Client 1ST Advisory Group LLC raised its holdings in Gilead Sciences by 4.0% during the third quarter. Client 1ST Advisory Group LLC now owns 1,786 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 69 shares in the last quarter. Davidson Trust Co. lifted its position in shares of Gilead Sciences by 4.1% during the 1st quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $262,000 after acquiring an additional 74 shares during the last quarter. Grove Bank & Trust lifted its holdings in shares of Gilead Sciences by 1.2% during the third quarter. Grove Bank & Trust now owns 6,345 shares of the biopharmaceutical company’s stock valued at $946,000 after purchasing an additional 74 shares during the last quarter. Financial Connections Group Inc. raised its holdings in Gilead Sciences by 30.2% during the 1st quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 76 shares during the period. Finally, Wilkerson Advisory Group LLC raised its holdings in Gilead Sciences by 54.2% during the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 78 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported positive Phase 2 SWIFT results for emvistegrast, an oral treatment for active ulcerative colitis. The drug met the trial’s primary goal, strengthening Gilead’s inflammatory bowel disease pipeline and potentially creating a future growth opportunity beyond its core HIV franchise. Gilead’s pill succeeds in mid-stage bowel disease trial
• Positive Sentiment: Gilead received a Zacks Rank upgrade to No. 2, or “Buy,” reflecting improved expectations for earnings and the possibility of continued near-term investor interest. Gilead rating upgrade to Buy
• Positive Sentiment: The company is scheduled to present 28 sets of HIV, HIV-prevention and antiviral research at IDWeek 2026, offering potential visibility into future products and additional clinical catalysts. Gilead to present new data at IDWeek 2026
• Neutral Sentiment: Reports noted that 43 exchange-traded funds added Gilead shares, indicating institutional demand, although ETF purchases are unlikely to materially change the company’s fundamentals. 43 ETFs add Gilead Sciences
• Neutral Sentiment: Recent acquisitions, including Arcellx and Tubulis, expand Gilead’s pipeline but raise questions about integration, costs and their effect on the steady profits and dividend investors expect from its HIV business. What has changed about owning Gilead stock
• Negative Sentiment: Two company insiders, Andrew Dickinson and Johanna Mercier, each reportedly sold 3,000 shares. These transactions may create a modest negative sentiment signal, although they are small relative to Gilead’s market value. Insider Andrew Dickinson sells shares Insider Johanna Mercier sells shares

Insider Activity

In other news, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $145.02, for a total value of $725,100.00. Following the transaction, the director owned 10,066 shares in the company, valued at $1,459,771.32. This represents a 33.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the completion of the transaction, the insider owned 113,684 shares in the company, valued at $17,759,714.48. This represents a 2.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 111,000 shares of company stock worth $15,877,860. Corporate insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on GILD. Needham & Company LLC reiterated a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a report on Wednesday, August 5th. Weiss Ratings raised shares of Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. HSBC boosted their price target on shares of Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Truist Financial boosted their price target on shares of Gilead Sciences from $150.00 to $158.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. Finally, Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Twenty-three analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $159.33.

Gilead Sciences Stock Down 2.0%

Shares of Gilead Sciences stock traded down $3.12 during midday trading on Monday, hitting $153.07. The company’s stock had a trading volume of 6,834,634 shares, compared to its average volume of 6,823,617. The firm has a market capitalization of $189.80 billion, a P/E ratio of -57.33 and a beta of 0.31. The stock has a 50-day simple moving average of $147.19 and a 200-day simple moving average of $137.29. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Gilead Sciences, Inc. has a 1-year low of $114.02 and a 1-year high of $160.51.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The business had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. Gilead Sciences’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.01 earnings per share. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post -0.47 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th were given a dividend of $0.82 per share. The ex-dividend date was Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.1%. Gilead Sciences’s dividend payout ratio (DPR) is presently -122.85%.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.